Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma – Authors' reply

[...]most censoring events were not due to treatment failure but, rather, due to patients continuing on imaging follow-up with no evidence of recurrence at the data cutoff date. The standard treatment for patients who relapse after nephrectomy is varied and might consist of close surveillance, local ablative therapies, surgery, or targeted therapy, especially in patients with favourable-risk disease as defined by the International mRCC Database Consortium criteria.5,6 Subsequent therapy data presented in KEYNOTE-564 represent the spectrum of treatments options currently used in the community. TKC reports institutional and personal support, paid and unpaid support for research, participating in advisory boards, consultancy, and honoraria from AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Pfizer, Roche, Sanofi/Aventis, Surface Oncology, Takeda, Tempest, UpToDate, and CME events (Peerview, OncLive, and MJH), outside the submitted work; institutional patents filed on molecular mutations, immunotherapy response and toxicity, and ctDNA; equity in Tempest, Pionyr, Osel, Precede Bio; being part of committees in the National Comprehensive Cancer Network, GU Steering Committee, American Society of Clinical Oncology, European Society for Medical Oncology, Academic and Community Cancer Research United, and KidneyCAN; having mentored several non-US citizens on research projects partly funded by non-US sources; and additional independent funding from drug companies or royalties for research around the subject matter paid to institution.